Kingsview Wealth Management LLC Buys New Shares in Stryker Corporation $SYK

Kingsview Wealth Management LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 18,669 shares of the medical technology company’s stock, valued at approximately $5,878,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Gables Capital Management Inc. acquired a new stake in shares of Stryker during the 2nd quarter valued at $25,000. Kilter Group LLC acquired a new position in shares of Stryker in the 2nd quarter worth $25,000. Godfrey Financial Associates Inc. acquired a new stake in shares of Stryker during the fourth quarter worth $26,000. Sankala Group LLC acquired a new stake in shares of Stryker during the fourth quarter worth $26,000. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker during the second quarter valued at $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Up 2.9%

NYSE:SYK opened at $331.32 on Friday. The business’s fifty day moving average price is $329.10 and its 200 day moving average price is $331.47. The firm has a market capitalization of $127.08 billion, a price-to-earnings ratio of 34.33, a PEG ratio of 2.05 and a beta of 0.76. The company has a current ratio of 2.16, a quick ratio of 1.33 and a debt-to-equity ratio of 0.59. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $396.86.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a return on equity of 23.63% and a net margin of 14.43%.The firm had revenue of $6.59 billion during the quarter, compared to analyst estimates of $6.58 billion. During the same period last year, the company posted $3.13 EPS. The business’s quarterly revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, sell-side analysts forecast that Stryker Corporation will post 15.02 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Wednesday, September 30th. Stryker’s dividend payout ratio (DPR) is currently 36.48%.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $340.10, for a total transaction of $17,005,000.00. Following the transaction, the director directly owned 2,251,375 shares of the company’s stock, valued at approximately $765,692,637.50. The trade was a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the transaction, the insider owned 6,210 shares in the company, valued at approximately $2,088,423. This represents a 11.74% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SYK. Wolfe Research lowered Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday, August 13th. Leerink Partners reduced their price objective on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research note on Friday, June 5th. Piper Sandler reduced their price objective on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Wells Fargo & Company decreased their target price on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Finally, Raymond James Financial set a $370.00 target price on shares of Stryker in a research report on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $386.28.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.